MX2007008196A - Taurine synthesis, production and utility as a medicine. - Google Patents
Taurine synthesis, production and utility as a medicine.Info
- Publication number
- MX2007008196A MX2007008196A MX2007008196A MX2007008196A MX2007008196A MX 2007008196 A MX2007008196 A MX 2007008196A MX 2007008196 A MX2007008196 A MX 2007008196A MX 2007008196 A MX2007008196 A MX 2007008196A MX 2007008196 A MX2007008196 A MX 2007008196A
- Authority
- MX
- Mexico
- Prior art keywords
- effective
- concentrations
- prevention
- combinations
- taurine
- Prior art date
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229960003080 taurine Drugs 0.000 title claims abstract description 20
- 230000015572 biosynthetic process Effects 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 239000002253 acid Substances 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 201000001883 cholelithiasis Diseases 0.000 claims description 4
- 208000001130 gallstones Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 206010008635 Cholestasis Diseases 0.000 claims description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004308 acetylcysteine Drugs 0.000 claims description 3
- 230000007870 cholestasis Effects 0.000 claims description 3
- 231100000359 cholestasis Toxicity 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 159000000011 group IA salts Chemical class 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000007863 steatosis Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000006277 sulfonation reaction Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 12
- 235000012000 cholesterol Nutrition 0.000 abstract description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract description 4
- 239000003833 bile salt Substances 0.000 abstract description 4
- 229940093761 bile salts Drugs 0.000 abstract description 4
- 239000004471 Glycine Substances 0.000 abstract description 2
- 241000124008 Mammalia Species 0.000 abstract description 2
- 239000003613 bile acid Substances 0.000 abstract description 2
- 230000029142 excretion Effects 0.000 abstract description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 abstract 1
- 239000003529 anticholesteremic agent Substances 0.000 abstract 1
- 229940127226 anticholesterol agent Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The quantitatively most important pathway for the excretion of cholesterol in mammals is the formation of bile salts (the conjugate bases of bile acids). The major bile salts are synthesized and secreted by as glycine or taurine conjugates. Taurine (2 aminoethyl sulphonic acid) is naturally produced by the liver cells and central nervous system cells, it is neuroprotective and is a cholesterol lowering agent with virtually no recorded side effects.
Description
SYNTHESIS, PRODUCTION AND UTILITY OF TAURINE AS A MEDICINE
FIELD OF THE INVENTION
Medicine. The quantitatively most important route for the excretion of cholesterol in mammals is the formation of bile salts (the conjugated bases of bile acids). The main bile salts are synthesized and secreted as conjugates of glycine or taurine.
BACKGROUND OF THE INVENTION
Taurine is a degradation product of cysteine. Taurine (2-aminoethylsulfonic acid) is a component of bile. It is combined with colic acid to form taurocholic acid. Colic acid is the metabolic fate of cholesterol. The formation of cholic acid involves a route that involves various hydroxylations and oxidation reactions. All water-soluble vitamins participate in these reactions. Taurine lowers cholesterol, and this action is potentiated by the presence of water-soluble vitamins. Taurine is effective in reducing hypercholesterolemia, hypertriglyceridemia and all disorders associated with lipids such as cholestasis or nephrotic syndrome, etc. It is also effective in any type of familial or idiopathic or acquired lipid disorder. Taurine is cardioprotective. Taurine is also effective in the dissolution of gallstones. Taurine is safe, and effective in normalizing high cholesterol, low density lipoproteins, or very low density lipoproteins. Taurine is also essential to stabilize brain cells against changes in blood osmolarity, and in the conversion of serotonin to endorphins. It is effective in depression, migraine, migraine, Alzheimer's disease and in psychiatric and neurological diseases.
SUMMARY OF THE INVENTION
The New Idea: To control: blood levels of lipids, lipoproteins, cholesterol, and diseases associated with hypercholesterolemia, psychiatric and neurological diseases and in the dissolution of gallstones, the following, individually or in combination, are effective: a. Taurine b. Cysteine and / or acetyl cysteine, c. All water-soluble vitamins.
DETAILED DESCRIPTION OF THE INVENTION
to. Taurine manufactured by all forms known as sulfonation of ethyl alcohol followed by substitution reaction in C2 or recombinant DNA technology to produce 2-aminoethyl-sulfonic acid or any possible way, or by the use of probiotics to promote the use of intestinal bacterial flora to recover taurine of taurocholic acid and tauroquenodeoxycholic acid etc ... previously formed in the liver. b. Acetyl cysteine is manufactured by all known forms. c. Water-soluble vitamins are manufactured by all known forms. Where: i. "a", "b" and "c" are all effective if they are given as
"a", or "b" or "c" or as "a + b", or "a + c"; or "b + c" or, "a + b + c". ii. "a", "b" and "c" are all effective if they are given as
"a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" when provided in oral or parenteral preparations or topical . iii. All and any composition and any and all concentrations of "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c "They are effective. iv. The taurine used comes in its acid form or acid salt or alkaline salt or in any of its compounds, or forms. v. The "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" in any and all concentrations and combinations are effective in the prevention and control of asterosclerosis and heart disease. saw. The "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" in any and all concentrations and combinations are effective in the prevention and control of all hypercholesterolemias, hypertriglycerides, and any and all lipid and lipoprotein disorders. vii. The "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" in any and all concentrations and combinations are effective in the prevention and control of disorders of cholestasis of any etiology. viii. The "a", or "b" or "c" or as "a + b", or "a + c", or
"b + c" or, "a + b + c" in any and all concentrations and combinations are effective in the prevention and control of steatosis of the liver and disorders of steatohepatitis of any etiology. ix. The "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" in any and all concentrations and combinations are effective in the prevention, dissolution and control of diseases of gallstones. x. The "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" in any and all concentrations and combinations are effective in the prevention and control of all psychiatric and neurological diseases.
Claims (10)
- NOVELTY OF THE INVENTION Having described the present invention, it is considered as a novelty and therefore the property described in the following claims is claimed as property.
- CLAIMS: a. Taurine manufactured by all forms known as sulfonation of ethyl alcohol followed by substitution reaction on C2 or recombinant DNA technology to produce 2-aminoethyl sulfonic acid or any possible way, or by the use of probiotics to promote the use of intestinal bacterial flora for recover taurine taurocholic acid and tauroquenodeoxycholic acid etc ... previously formed in the liver. b. Acetyl cysteine is manufactured by all known forms. c. Water-soluble vitamins are manufactured by all known forms. Where: 1. "a", "b" and "c" are all effective if they are given as "a", or "b" or "c" or as "a + b", or "a + c"; or "b + c" or, "a + b + c". 2. "a", "b" and "c" are all effective if they are given as "a", or "b" or "c" or as "a + b", or "a + c", or "b" + c "o," a + b + c "when provided in oral, parenteral or topical preparations.
- 3. All and any composition and any and all concentrations of "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c "They are effective.
- 4. The taurine used comes in its acid form or acid salt or alkaline salt or in any of its compounds, forms or configurations.
- 5. The "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" at any and all concentrations and combinations are effective in the prevention and control of asterosclerosis and heart disease.
- 6. The "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" at any and all concentrations and combinations are effective in the prevention and control of all hypercholesterolemias, hypertriglycerides, and any and all lipid and lipoprotein disorders.
- 7. The "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" at any and all concentrations and combinations are effective in the prevention and control of cholestasis disorders of any etiology.
- 8. The "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" at any and all concentrations and combinations are effective in the prevention and control of steatosis of the liver and disorders of steatohepatitis of any etiology.
- 9. The "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" at any and all concentrations and combinations are effective in prevention, and in controlling diseases of gallstones.
- 10. The "a", or "b" or "c" or as "a + b", or "a + c", or "b + c" or, "a + b + c" in any and all concentrations and combinations are effective in the prevention and control of all psychiatric and neurological diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EG2005010013 | 2005-01-05 | ||
| PCT/EG2005/000044 WO2006072259A2 (en) | 2005-01-05 | 2005-12-31 | Taurine synthesis, production and utility as a medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007008196A true MX2007008196A (en) | 2008-02-22 |
Family
ID=36647837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007008196A MX2007008196A (en) | 2005-01-05 | 2005-12-31 | Taurine synthesis, production and utility as a medicine. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1844006A2 (en) |
| JP (1) | JP2008526789A (en) |
| KR (1) | KR20070091198A (en) |
| CN (1) | CN101146767A (en) |
| AP (1) | AP2007004084A0 (en) |
| AU (1) | AU2005324199A1 (en) |
| BR (1) | BRPI0519606A2 (en) |
| CA (1) | CA2593563A1 (en) |
| EA (1) | EA200701434A1 (en) |
| IL (1) | IL184221A0 (en) |
| MA (1) | MA29238B1 (en) |
| MX (1) | MX2007008196A (en) |
| NO (1) | NO20074937A (en) |
| TN (1) | TNSN07226A1 (en) |
| WO (1) | WO2006072259A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5583022B2 (en) | 2007-11-30 | 2014-09-03 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | Method for treating non-alcoholic steatohepatitis (NASH) using cysteamine product |
| CN103382170B (en) * | 2012-10-25 | 2015-04-08 | 潜江永安药业股份有限公司 | Preparation method for taurine |
| CN106728405A (en) * | 2016-11-15 | 2017-05-31 | 陈思文 | A kind of taurine and water soluble tea polyphenol compound and preparation method and application |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58140017A (en) * | 1981-12-22 | 1983-08-19 | Junichi Azuma | Remedy for cardiac insufficiency |
| JPH08208464A (en) * | 1994-12-02 | 1996-08-13 | Taisho Pharmaceut Co Ltd | Treatment and prevention drug for hyperlipidemia |
| US6184227B1 (en) * | 1995-07-21 | 2001-02-06 | Savvipharm Inc. | Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases |
| SE9601395D0 (en) * | 1996-04-12 | 1996-04-12 | Dieter Haeussinger | New therapeutic treatment 1 |
| GB9722361D0 (en) * | 1997-10-24 | 1997-12-17 | Pharma Nord Uk Ltd | Pharmaceutical formulation for treating liver disorders |
| NZ527924A (en) * | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
| WO2001026642A2 (en) * | 1999-10-08 | 2001-04-19 | Joyce Corinne Bechthold | Methods and compositions for treating neurobehavioral disorders |
| CN1340502A (en) * | 2000-06-30 | 2002-03-20 | 张永春 | Process for preparing taurine zinc |
| CN1268733C (en) * | 2004-07-20 | 2006-08-09 | 刘辉 | Taurine functional beer and its producing process |
-
2005
- 2005-12-31 MX MX2007008196A patent/MX2007008196A/en not_active Application Discontinuation
- 2005-12-31 WO PCT/EG2005/000044 patent/WO2006072259A2/en not_active Ceased
- 2005-12-31 CA CA002593563A patent/CA2593563A1/en not_active Abandoned
- 2005-12-31 EA EA200701434A patent/EA200701434A1/en unknown
- 2005-12-31 AP AP2007004084A patent/AP2007004084A0/en unknown
- 2005-12-31 BR BRPI0519606-0A patent/BRPI0519606A2/en not_active IP Right Cessation
- 2005-12-31 EP EP05818935A patent/EP1844006A2/en not_active Withdrawn
- 2005-12-31 JP JP2007549796A patent/JP2008526789A/en active Pending
- 2005-12-31 CN CNA2005800460663A patent/CN101146767A/en active Pending
- 2005-12-31 KR KR1020077016443A patent/KR20070091198A/en not_active Withdrawn
- 2005-12-31 AU AU2005324199A patent/AU2005324199A1/en not_active Abandoned
-
2007
- 2007-06-14 TN TNP2007000226A patent/TNSN07226A1/en unknown
- 2007-06-26 IL IL184221A patent/IL184221A0/en unknown
- 2007-07-26 MA MA30110A patent/MA29238B1/en unknown
- 2007-09-28 NO NO20074937A patent/NO20074937A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN07226A1 (en) | 2008-11-21 |
| JP2008526789A (en) | 2008-07-24 |
| NO20074937A (en) | 2007-09-28 |
| AP2007004084A0 (en) | 2007-08-31 |
| MA29238B1 (en) | 2008-02-01 |
| WO2006072259A3 (en) | 2007-10-04 |
| WO2006072259A2 (en) | 2006-07-13 |
| EP1844006A2 (en) | 2007-10-17 |
| CA2593563A1 (en) | 2006-07-13 |
| KR20070091198A (en) | 2007-09-07 |
| BRPI0519606A2 (en) | 2009-02-25 |
| CN101146767A (en) | 2008-03-19 |
| IL184221A0 (en) | 2008-12-29 |
| AU2005324199A1 (en) | 2006-07-13 |
| EA200701434A1 (en) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI634888B (en) | Novel highly penetrating drugs and pharmaceutical compositions for treating Parkinson's disease | |
| US20160058719A1 (en) | Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis | |
| JPH07501539A (en) | Organic salt of N,N'-diacetylcystine | |
| JP2022510691A (en) | Compositions for the treatment of fibrosis and inflammation | |
| EP0951909B1 (en) | Combination composition comprising a L-carnitine or an alkanoyl-L-carnitine, a glycosaminoglycan and/or constituent thereof | |
| CN111971290B (en) | Glucosamine derivatives for preventing or treating joint diseases | |
| ES2974212T3 (en) | Nicotinamide mononucleotide derivatives in the treatment and prevention of sickle cell disease | |
| CN102711720B (en) | Pigmentation prevention or improvement agent | |
| AU2019217990B2 (en) | Methods for treating mitochondrial disorders | |
| JP5671483B2 (en) | Pigmentation preventing or improving agent | |
| MX2007008196A (en) | Taurine synthesis, production and utility as a medicine. | |
| JP7073384B2 (en) | Compounds and usage | |
| Gupta | Taurine analogues and taurine transport: therapeutic advantages | |
| WO2011030727A1 (en) | External preparation containing pantethine phosphate ester | |
| AU2024208147A1 (en) | Amino lipid compound, and preparation method therefor and use thereof | |
| Durand et al. | Synthesis and antioxidant efficiency of a new amphiphilic spin-trap derived from PBN and lipoic acid | |
| EP1234816B1 (en) | Scyphostatin analogues as SMase inhibitors | |
| JP2024041865A (en) | Novel highly permeable drugs and compositions thereof for the treatment of Parkinson's disease | |
| US8697898B2 (en) | Medical application of lipid derivatives of dopamine and the methods of their production | |
| EP2324824B1 (en) | Medical application of a lipid derivative of dopamine | |
| JP7680443B2 (en) | Synergistic nutritional composition for improving ATP efficiency | |
| CN115594724A (en) | Glucosamine derivatives for preventing or treating joint diseases | |
| JP2013001659A (en) | Skin care preparation | |
| JP6596483B2 (en) | Novel high-permeability drug and its composition for treating Parkinson's disease | |
| HK40047839B (en) | Novel high penetration drugs and pharmaceutical compositions thereof for treatment of parkinson diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |